Skip to main content
Clinical Trials/CTRI/2022/01/039227
CTRI/2022/01/039227
Completed
未知

Efficacy of Nicorandil as an add-on therapy to standard treatment in acute ischemic stroke- A Randomized, single blind, controlled clinical trial - ENCORE

SRMIST0 sites19 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: G94- Other disorders of brain in diseases classified elsewhere
Sponsor
SRMIST
Enrollment
19
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
April 14, 2023
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
SRMIST

Eligibility Criteria

Inclusion Criteria

  • Age 18 \-75 years.
  • \-Both genders.
  • \-Diagnosis of acute ischemic stroke.
  • \-More than 24 hours of onset of symptoms and not greater than 96 hours.
  • \-Modified Rankin scale greater than two.
  • \-Ability to ingest oral medication.
  • \-BMI \>18\.5 kg /m².

Exclusion Criteria

  • Haemorrhagic stroke.
  • Hypotension with a SBP \< 100 mmHg.
  • Patients on ACEIs and ARBs.
  • Patients on steroids.
  • Patients with respiratory compromise.
  • Patients on antidepressant drugs.
  • Severe acid peptic disease.
  • Kidney dysfunction (GFR \< 30ml /min).
  • Intake of NSAID (exemption of Paracetamol).
  • Severe unstable medical illnesses, including uncontrolled cardiac conditions or heart failure, cardiogenic shock (New York Heart Association Class III or IV).

Outcomes

Primary Outcomes

Not specified

Similar Trials